Correlation between histological subtypes of invasive lung adenocarcinoma and epithelial growth factor receptor (EGFR) gene mutation_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

WANG Likun , ZHOU Xuan , DU Tianyu , ZHAO Erlin ,  XIAO Xuyang

Department of Thoracic Surgery, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, 121000, Liaoning, P.R.China;

Corresponding author：

XIAO Xuyang, Email: xiaoxuyang1234@163.com

Keywords：

Lung adenocarcinoma; histological subtype; epithelial growth factor receptor; gene mutation; treatment

DOI：

10.7507/1007-4848.201909012

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the correlation between histological subtypes of invasive lung adenocarcinoma and epithelial growth factor receptor (EGFR) gene mutation, and to provide a reference for clinical prediction of EGFR gene mutation status.Methods From October 2017 to May 2019, 102 patients with invasive lung adenocarcinoma were collected, including 58 males and 44 females aged 62 (31-84) years. Invasive lung adenocarcinoma was classified into different histological subtypes. Scorpion probe amplification block mutation system (ARMS) real-time PCR was used to detect the mutation of EGFR gene in adenocarcinoma specimens, and the relationship between invasive lung adenocarcinoma subtypes and EGFR mutation status was analyzed.Results In 102 patients with invasive lung adenocarcinoma, EGFR gene mutations were detected in 68 patients, and the mutation rate was 66.7% (68/102). The mutation sites were mainly concentrated in the exons 19 and 21; the mutation rate was higher in female patients (34/44, 77.3%) and non-smokers (34/58, 58.6%). EGFR mutation was mostly caused by acinar-like invasive lung adenocarcinoma, and was rare in solid-type lung adenocarcinoma. The EGFR gene mutation rates in different subtypes of adenocarcinoma were statistically different (P<0.05).Conclusion The EGFR mutation status is related to gender, smoking status and histological subtype of invasive lung adenocarcinoma. EGFR mutation rates are higher in female, non-smoking and acinar-like invasive lung adenocarcinoma patients, and are lower in patients with solid type lung adenocarcinoma.

Citation： WANG Likun, ZHOU Xuan, DU Tianyu, ZHAO Erlin, XIAO Xuyang. Correlation between histological subtypes of invasive lung adenocarcinoma and epithelial growth factor receptor (EGFR) gene mutation. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2020, 27(7): 780-783. doi: 10.7507/1007-4848.201909012 Copy

1.	Rebecca LS, Kimberly DM, Ahmedin J. Cancer statistics, 2016. CA: Cancer J Clin, 2016, 66(1): 7-30.
2.	尹光浩, 刘伟, 刘国津, 等. 非小细胞肺癌的 EGFR 表达与 EGFR 基因突变的比较. 中国实验诊断学, 2009, 13(2): 200-202.
3.	Bronte G, Rolfo C, Giovannetti E, et al. Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects. Crit Rev Oncol Hematol, 2014, 89(2): 300-313.
4.	Travis WD, Brambilla E, Noguchi MT, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc Am Thorac Soc, 2011, 8(5): 381-385.
5.	Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol, 2015, 10(9): 1243-1260.
6.	Hirsch FR, Bunn PAJ. EGFR testing in lung cancer is ready for prime time. Lancet Oncol, 2009, 10(5): 432-433.
7.	凌云, 邱田, 李卓, 等. 非小细胞肺癌中 EGFR 和 KRAS 基因突变的特点及与临床病理特征的关系. 临床与实验病理学杂志, 2015, 31(5): 536-541.
8.	肖芸, 罗辉, 黄敏. 表皮生长因子受体基因突变对非小细胞肺癌临床病理与酪氨酸激酶抑制剂疗效的影响. 中国老年学杂志, 2017, 37(23): 5849-5851.
9.	Kim KS, Jeong JY, Kim YC, et al. Predictors of the response to gefitinib in refractory non-small cell lung cancer. Clin Cancer Res, 2005, 11(6): 2244-2251.
10.	Chaft JE, Arcila ME, Paik PK, et al. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. Mol Cancer Ther, 2012, 11(2): 485-491.
11.	Li H, Pan Y, Li Y, et al. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose. Lung Cancer, 2013, 79(1): 8-13.
12.	Nakamura H, Saji H, Shinmyo T, et al. Association of IASLC/ATS/ERS histologic subtypes of lung adenocarcinoma with epidermal growth factor receptor mutations in 320 resected cases. Clin Lung Cancer, 2015, 16(3): 209-215.
13.	Villa C, Cagle PT, Johnson M, et al. Correlation of EGFR mutation status with predominant histologic subtype of adenocarcinoma according to the new lung adenocarcinoma classification of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society. Arch Pathol Lab Med, 2014, 138(10): 1353-1357.
14.	Russell PA, Wainer Z, Wright GM, et al. Does lung adenocarcinoma subtype predict patient survival?: A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol, 2011, 6(9): 1496-1504.
15.	Kamiya K, Hayashi Y, Douguchi J, et al. Histopathological features and prognostic significance of the micropapillary pattern in lung adenocarcinoma. Mod Pathol, 2008, 21(8): 992-1001.
16.	Shim HS, Lee DH, Park EJ, et al. Histopathologic characteristics of lung adenocarcinomas with epidermal growth factor recetor mutations in the International Association for the Study of Lung Cancer/Amertican Thoracic Society/Eruopean Respiratory Society lung adenocarcinoma classification. Arch Pathol Lab Meb, 2011, 135(10): 1329-1334.
17.	Inamura K, Ninomiya H, Ishikawa Y, et al. Is the epidermal growth factor receptor status in lung cancers reflected in clinicopathologic features? Arch Pathol Lab Med, 2010, 134(1): 66-72.

1. Rebecca LS, Kimberly DM, Ahmedin J. Cancer statistics, 2016. CA: Cancer J Clin, 2016, 66(1): 7-30.
2. 尹光浩, 刘伟, 刘国津, 等. 非小细胞肺癌的 EGFR 表达与 EGFR 基因突变的比较. 中国实验诊断学, 2009, 13(2): 200-202.
3. Bronte G, Rolfo C, Giovannetti E, et al. Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects. Crit Rev Oncol Hematol, 2014, 89(2): 300-313.
4. Travis WD, Brambilla E, Noguchi MT, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc Am Thorac Soc, 2011, 8(5): 381-385.
5. Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol, 2015, 10(9): 1243-1260.
6. Hirsch FR, Bunn PAJ. EGFR testing in lung cancer is ready for prime time. Lancet Oncol, 2009, 10(5): 432-433.
7. 凌云, 邱田, 李卓, 等. 非小细胞肺癌中 EGFR 和 KRAS 基因突变的特点及与临床病理特征的关系. 临床与实验病理学杂志, 2015, 31(5): 536-541.
8. 肖芸, 罗辉, 黄敏. 表皮生长因子受体基因突变对非小细胞肺癌临床病理与酪氨酸激酶抑制剂疗效的影响. 中国老年学杂志, 2017, 37(23): 5849-5851.
9. Kim KS, Jeong JY, Kim YC, et al. Predictors of the response to gefitinib in refractory non-small cell lung cancer. Clin Cancer Res, 2005, 11(6): 2244-2251.
10. Chaft JE, Arcila ME, Paik PK, et al. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. Mol Cancer Ther, 2012, 11(2): 485-491.
11. Li H, Pan Y, Li Y, et al. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose. Lung Cancer, 2013, 79(1): 8-13.
12. Nakamura H, Saji H, Shinmyo T, et al. Association of IASLC/ATS/ERS histologic subtypes of lung adenocarcinoma with epidermal growth factor receptor mutations in 320 resected cases. Clin Lung Cancer, 2015, 16(3): 209-215.
13. Villa C, Cagle PT, Johnson M, et al. Correlation of EGFR mutation status with predominant histologic subtype of adenocarcinoma according to the new lung adenocarcinoma classification of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society. Arch Pathol Lab Med, 2014, 138(10): 1353-1357.
14. Russell PA, Wainer Z, Wright GM, et al. Does lung adenocarcinoma subtype predict patient survival?: A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol, 2011, 6(9): 1496-1504.
15. Kamiya K, Hayashi Y, Douguchi J, et al. Histopathological features and prognostic significance of the micropapillary pattern in lung adenocarcinoma. Mod Pathol, 2008, 21(8): 992-1001.
16. Shim HS, Lee DH, Park EJ, et al. Histopathologic characteristics of lung adenocarcinomas with epidermal growth factor recetor mutations in the International Association for the Study of Lung Cancer/Amertican Thoracic Society/Eruopean Respiratory Society lung adenocarcinoma classification. Arch Pathol Lab Meb, 2011, 135(10): 1329-1334.
17. Inamura K, Ninomiya H, Ishikawa Y, et al. Is the epidermal growth factor receptor status in lung cancers reflected in clinicopathologic features? Arch Pathol Lab Med, 2010, 134(1): 66-72.

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Correlation between histological subtypes of invasive lung adenocarcinoma and epithelial growth factor receptor (EGFR) gene mutation

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content